Company: MIRA
Filing Date: 2025-06-17
Form Type: PREM14A
Source: 0001641172-25-015340
Chunk: 165

Company: MIRA PHARMACEUTICALS, INC.
Filing Date: 2025-06-17
Form: PREM14A
Chunk 165
---
     |  7 |
| Methodology     |     | 14 |
| Valuation       |     | 17 |
| Appendix        
 – Discount Rate |     | 24 |
| Appendix        
 – Peer group    |     | 25 |

| Moore Financial Consulting |

| SKNY Pharmaceuticals, Inc. | April 2025   |
| Valuation                  | Page 6 of 25 |

The Company

SKNY Pharmaceuticals, Inc. (“SKNY”, or the “Company”) was founded in the United States as a private company.

The company’s field of activity is oral therapy; it developed a synthetic cannabinoid analog of THCV with unique receptor-interacting properties, SKNY-1 (hereinafter: “SKNY-1”, “analog”). The analog’s properties allow it to be effective in treating Nicotine dependence, smoking cessation, and weight loss.

Studies show that SKNY-1 can improve efficacy with a benight safety profile that will be attractive in the Nicotine dependence, Smoking cessation, and Weight loss markets.

SKNY-1 serves as a CB1 blocker, CB2 activator, and MOA inhibitor and stops the reward sensation in smokers. Nicotine withdrawal effects are common with OTC medications for Nicotine dependence; by avoiding these effects, SKNY-1 provides a more efficient therapeutic option.

Furthermore, SKNY1 is assumed to restore insulin sensitivity, decrease appetite, increase satiety, and up-regulate energy metabolism without safety issues.

According to the company, SKNY-1 is designed to offer superior efficacy to other oral anti-obesity medications while improving safety and tolerability, addressing key concerns, and improving compliance.

License agreement

MIRALOGX, LLC (hereinafter “Miralogx”) is a biotechnology company developing innovative, patented molecules to develop novel drugs for various healthcare solutions through exclusive licensing and strategic partnerships.

The company and Miralogx entered into a license agreement for SKNY-1. The agreement clarifies that the licensor (Miralogx) is the owner of the intellectual property. In addition, SKNY agrees to pay Miralogx 8.0% of all revenues (Net sales Price), excluding any commercial sales accounted for in the Net Sales Price, with a minimum annual payment of $250,000$. SKNY license is for the North American Territories (US, Canada and Mexico).

To the extent SKNY grants a sublicense to any third party and receives revenue, SKNY agrees to pay Miralogx 8.0